First day of the Southeast Venture Showcase - Need more description
Start your day with a selection of pastries, fruit, and coffee while connecting with fellow attendees and preparing for a day of innovation and insights at the SVS Showcase.
Welcome to the SVS Showcase! Stephen Miller will kick off the day with a warm welcome, followed by Patrick Driscoll from Holland & Knight.
Join leading venture capitalists as they discuss the evolving startup landscape in the Southeast. Learn how regional funds are driving innovation, supporting emerging companies, and reshaping the path to growth for local startups.
Nemea Therapeutics is a preclinical-stage company developing oral small molecule inhibitors targeting mitochondrial RNA polymerase (POLRMT) for the treatment of mitochondria-dependent solid tumors.
Annoviant is advancing patient outcomes in heart disease by delivering innovative, regenerative cardiovascular devices built on its proprietary TxGuard™ soft-tissue technology.
The platform enables durable, off-the-shelf solutions that address critical unmet needs in heart valve disease and coronary artery bypass grafting—helping patients live healthier lives while reducing long-term healthcare costs.
Avast Therapeutics is developing first-in-class, non-invasive peptide therapeutics that safely cross the blood-brain barrier to restore mitochondrial function and protect neurons.
This breakthrough approach targets neurodegenerative diseases such as Parkinson’s and Alzheimer’s at their earliest stages, with the potential to halt disease progression and transform brain medicine.
Bluegrass Pharmaceuticals develops advanced Lipid Nanoparticles (LNPs) to enhance vaccine efficacy and enable targeted therapeutic delivery.
Connect with fellow attendees, innovators, and industry leaders. Share ideas, explore collaborations, and build relationships that can drive the future of healthcare technology.
Kifa Therapeutics advances highly selective CNS-kinase inhibitors, starting with a G2019S-LRRK2 therapy for Parkinson’s disease.
Our strategy pairs genetics-based patient selection with validated biomarkers to enable efficient clinical studies and an orphan, accelerated-approval path.
SelSym Biotech is pioneering hemostasis with SymClot, an innovative platelet-mimetic therapy that promises to dramatically improve patient survival and outcomes by rapidly stopping bleeding after severe trauma and high-risk surgeries.
